ICD-10 Code A30.4 | Borderline lepromatous leprosy Symptoms, Diagnosis, Billing

Borderline lepromatous leprosy is a form of leprosy characterized by a moderate immune response to Mycobacterium leprae. It presents with skin lesions, nerve damage, and potential disability. Accurate coding with ICD-10 Code A30.4 is essential for proper diagnosis, documentation, medical billing, and public health reporting, ensuring appropriate treatment and resource allocation.

What is ICD-10 Code A30.4 for Borderline lepromatous leprosy?

ICD-10 Code A30.4 represents Borderline lepromatous leprosy, a subtype of leprosy where patients exhibit a mix of both tuberculoid and lepromatous features. This code is used in clinical documentation and billing when diagnosing patients with this condition, ensuring accurate representation of the disease's severity and facilitating appropriate treatment plans.

ICD-10 Code A30.4 – Clinical Definition and Explanation of Borderline lepromatous leprosy

Borderline lepromatous leprosy is caused by the bacterium Mycobacterium leprae, leading to skin lesions and peripheral nerve damage. This condition requires medical attention due to its potential for causing significant morbidity if left untreated. Early diagnosis and intervention are crucial for effective management.

Key Clinical Features:

• Presence of skin lesions that may be hypopigmented or erythematous.
• Nerve involvement leading to sensory loss or weakness.
• Potential for disability if not treated promptly.
• Variable immune response, with some patients showing signs of tuberculoid leprosy.

ICD-10 Code A30.4 for Borderline lepromatous leprosy – SOAP Notes & Clinical Use

ICD-10 Code A30.4 is utilized in SOAP notes to document the patient's symptoms, assessment findings, and treatment plans. It is relevant in both acute and chronic care settings, ensuring comprehensive documentation of the patient's condition and facilitating continuity of care.

What Does ICD-10 Code A30.4 for Borderline lepromatous leprosy Mean in SOAP Notes?

In SOAP notes, ICD-10 Code A30.4 connects subjective patient-reported symptoms with objective clinical findings, leading to a formal diagnosis. This code supports continuity of care, aids in billing processes, and meets EHR documentation standards.

Treatment Options for ICD-10 Code A30.4 – Borderline lepromatous leprosy

Borderline lepromatous leprosy requires prompt treatment to prevent complications. Hospitalization may be necessary for severe cases, and appropriate antibiotic therapy is essential.

Antibiotic Therapy:

• Dapsone: 100 mg daily.
• Rifampicin: 600 mg monthly.
• Clofazimine: 300 mg monthly, with 50 mg daily.

Supportive Care:

• Regular monitoring of skin lesions and nerve function.
• Physical therapy to maintain mobility and function.
• Psychosocial support for affected individuals.

Infection Control:

• Implement standard precautions to prevent transmission.
• Educate patients on hygiene practices.
• Monitor for outbreaks in endemic areas.

How to Document Symptoms of Borderline lepromatous leprosy (ICD-10 A30.4) in SOAP Notes

Subjective:

• Patient reports numbness and tingling in hands and feet.
• History of skin lesions that have not healed.
• Complaints of weakness in the extremities.
• Patient expresses concern about potential disability.

Objective:

• Skin examination reveals hypopigmented lesions on the arms and legs.
• Decreased sensation noted in the ulnar and median nerve distributions.
• Nerve conduction studies show delayed responses.
• Vital signs within normal limits.

Secure, compliant, and built for trust

HIPAA-compliant and designed with privacy in mind, your patient’s data is protected. Focus on care while we safeguard your information.

Learn more

SOAP Note Guidelines for Diagnosing Borderline lepromatous leprosy (ICD-10 Code A30.4)

Assessment:

• Diagnosis: Borderline lepromatous leprosy (ICD-10 A30.4).
• Severity: Moderate, with significant nerve involvement.
• Contributing factors: Possible exposure to Mycobacterium leprae.
• Triggers: Immune response variability.

Plan:

• Initiate treatment with Dapsone and Rifampicin.
• Schedule follow-up appointments for monitoring.
• Educate patient on skin care and symptom management.
• Refer to physical therapy for rehabilitation.

Treatment & Plan Section for ICD-10 Code A30.4 – Borderline lepromatous leprosy

• First-line pharmacologic treatments include Dapsone and Rifampicin.
• Non-pharmacologic strategies involve regular skin care and physical therapy.
• Monitoring practices include regular assessments of nerve function.
• Follow-up recommendations should be scheduled every 1-3 months.

Using ICD-10 Code A30.4 for Borderline lepromatous leprosy in Billing & SOAP Note Compliance

• Select accurate subcodes based on clinical severity or complications.
• Document symptoms clearly under Subjective (S) and Objective (O) in SOAP notes.
• Ensure treatment plans align with clinical guidelines to support justified billing.
• List CPT codes commonly billed with ICD-10 Code A30.4 based on standard practices.

Related ICD-10 Codes Often Used with Borderline lepromatous leprosy

• A30.0 – Lepromatous leprosy
• A30.1 – Tuberculoid leprosy
• A30.2 – Borderline tuberculoid leprosy
• A30.3 – Borderline leprosy

ICD-10 Code A30.4 in Medical Billing and Insurance for Borderline lepromatous leprosy

ICD-10 Code A30.4 is crucial for billing in hospital, ER, or infectious disease care settings.

Billing Notes:

• Ensure documentation includes detailed patient history and clinical findings.
• Use the code in settings where leprosy treatment is provided.
• Highlight key chart elements such as treatment plans and follow-up care.

Common CPT Pairings: